Recombinant human adenovirus type 5 administration for the treatment of malignant ascites or pleural effusion in cancer patients: a meta-analysis.
Changsong Duan, Xue Liu
https://pubmed.ncbi.nlm.nih.gov/41040530/Actively Recruiting
Led by Jie Yuan,MD · Updated on 2026-09-30
15
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are investigating the use of intratumoral H101 oncolytic virus combined with immune checkpoint inhibitors ICIs in patients with advanced Stage IV breast cancer who have not responded to multiple prior treatments. This prospective, single-center, open-label, real-world observational study aims to preliminarily assess the antitumor activity, safety, and changes in the tumor immune microenvironment caused by this combination therapy in 10 to 15 patients aged 18 to 75 years with measurable and injectable lesions. The treatment framework includes 2- to 3-week cycles for a total of 4 planned cycles. On day 1 of each cycle, H101 is injected directly into tumors, with the dose adjusted by lesion size. ICIs, including anti-PD-1 and optionally anti-CTLA-4 antibodies, are infused intravenously 7 2 days after the H101 injection. The exact regimen is decided by physicians based on individual patient status and multidisciplinary advice. Tumor biopsies and blood samples are collected before treatment and after 4 cycles to analyze immune cell changes and gene expression. Participants undergo regular assessments including radiographic evaluations starting 6-8 weeks after treatment completion and every 3 months thereafter for up to one year or until disease progression. Safety is monitored through adverse event reporting using standardized criteria. Researchers measure outcomes such as objective tumor response, local lesion control, disease control rate, progression-free survival, and immune environment changes. The study includes comprehensive follow-up and data protection to ensure participant safety and scientific rigor.
CONDITIONS
A Real-World Observational Study of Intratumoral H101 Oncolytic Adenovirus Combined With Immune Checkpoint Inhibitors for Advanced Metastatic Breast Cancer
J
Jie Yuan, Doctoral degree
J
Jie Yuan
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Jie Yuan,MD
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 8 to 12 weeks
Participants receive intratumoral injections of H101 and intravenous infusions of immune checkpoint inhibitors over four 2- to 3-week cycles.
Once per treatment cycle
Duration - Up to 1 year
Participants undergo radiographic assessments starting 6-8 weeks after treatment and every 3 months for up to one year to monitor tumor response and safety.
Periodic visits every 3 months
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Changsong Duan, Xue Liu
https://pubmed.ncbi.nlm.nih.gov/41040530/Qiu Zhao, Min Xiao, Jian Ma...
https://pubmed.ncbi.nlm.nih.gov/39588306/Qiying Zhang, Jing Zhang, Zi Liu...
https://pubmed.ncbi.nlm.nih.gov/38046281/Zhi-Ming Wang, Meng-Kai Li, Qing-Ling Yang...
https://pubmed.ncbi.nlm.nih.gov/39030309/Jing Zhang, Qiying Zhang, Zi Liu...
https://pubmed.ncbi.nlm.nih.gov/35574359/Jie Yuan,MD
Lead Sponsor